IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study
- 1 April 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 206 (7) , 1569-1575
Abstract
The IL-1 receptor antagonist, anakinra, may represent a therapeutic option for acute respiratory distress syndrome (ARDS) associated with coronavirus disease 2019 (COVID-19). In this study, COVID-19 ARDS patients admitted to the Azienda Socio Sanitaria Territoriale of Lecco, Italy, between March 5th to April 15th, 2020, and who had received anakinra off-label were retrospectively evaluated and compared with a cohort of matched controls who did not receive immunomodulatory treatment. The primary end point was survival at day 28. The population consisted of 112 patients (56 treated with anakinra and 56 controls). Survival at day 28 was obtained in 69 patients (61.6%) and was significantly higher in anakinra-treated patients than in the controls (75.0 versus 48.2%, p = 0.007). When stratified by continuous positive airway pressure support at baseline, anakinra-treated patients’ survival was also significant compared with the controls (p = 0.008). Univariate analysis identified anakinra usage (odds ratio, 3.2; 95% confidence interval, 1.47–7.17) as a significant survival predictor. This was not supported by multivariate modeling. The rate of infectious-related adverse events was similar between groups. In conclusion, anakinra improved overall survival and invasive ventilation-free survival and was well tolerated in patients with ARDS associated with COVID-19. Key Points Anakinra improved 28-day survival rate in patients with COVID-19–associated ARDS. Anakinra was well tolerated, with no increase in infection-related adverse events.Keywords
This publication has 24 references indexed in Scilit:
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory FailureCell Host & Microbe, 2020
- Covid-19 in Critically Ill Patients in the Seattle Region — Case SeriesNew England Journal of Medicine, 2020
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathyJournal of Thrombosis and Haemostasis, 2020
- Continuous Intravenous Anakinra Infusion to Calm the Cytokine Storm in Macrophage Activation SyndromeACR Open Rheumatology, 2020
- Respiratory support for patients with COVID-19 infectionThe Lancet Respiratory Medicine, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation SyndromeCritical Care Medicine, 2016
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trialsRheumatology, 2010